1Herbst RS. Role of novel targeted therapies in the clinic. Br J Cancer, 2005,92 Suppl 1 : S21-S27.
2O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol, 1997,15 ( 1 ) :246-250.
3Reiter JL, Threadgill DW, Eley GD, et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics, 2001,71 (1) :1-20.
4Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol, 2003, 30(3 Suppl 6) :39-50.
6Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol, 2002, 20 (18): 3898-3905.
7DeMatteo RP. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol, 2002, 9(9) : 831-839.
8Maki RG, Fletcher JA, Heinrich MC, et al. Results from a continuation trial of SU11248 in patients ( pts ) with imatinib ( IM )-resistant gastrointestinal stromal tumor ( GIST ). Proc ASCO ,2005, Abstr 9011.
9Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001, 438(1) :1-12.
